PUBLISHER: IMARC | PRODUCT CODE: 1540827
PUBLISHER: IMARC | PRODUCT CODE: 1540827
The global molecular cytogenetics market size reached US$ 2.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.0 Billion by 2032, exhibiting a growth rate (CAGR) of 9.1% during 2024-2032.
Molecular cytogenetics refers to the biomedical research of deoxyribonucleic acid (DNA) mechanisms to investigate genetic mutations and disorders. It studies the structural and functional organization of the chromosomes and their nucleus, genomic variations, expression, evolution and abnormalities, especially in medicinal and cancer-related genetics. Techniques such as DNA amplification, DNA isolation, gene screens, virtual karyotyping and fluorescence in situ hybridization (FISH) are commonly used for molecular cytogenetics by using DNA probes to visualize and label the genome or its targeted regions. These techniques are highly beneficial in the diagnosis and treatment of various malignant tumors and hematological malignancies.
The increasing prevalence of cancer and other genetic disorders, along with the rising geriatric population, is one of the key factors driving the growth of the market. Molecular cytogenetics is primarily being used for developing predictive models of disease traits and effective treatment strategies. Furthermore, the widespread adoption of targeted therapies for cancer treatment is also augmenting the market growth. FISH and Comparative Genomic Hybridization (CGH) are also used for pharmacogenomic biomarker studies to analyze cancer progression stages and provide personalized treatment to the patient. Additionally, various technological advancements, such as the development of improved consumables, reagents, software and kits, are acting as other growth-inducing factors. These advancements aid in generating duplicatable, accurate and reliable clinical-pathological test results. Other factors, including significant improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities in the field of biomedical sciences, are anticipated to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global molecular cytogenetics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, technology, application and end user.
Instruments
Consumables
Software and Services
Others
Comparative Genomic Hybridization
Fluorescence in SITU Hybridization (FISH)
Immunohistochemistry
Karyotyping
Others
Genetic Disorders
Oncology
Personalized Medicine
Others
Clinical and Research Laboratories
Hospitals and Pathology Laboratories
Pharmaceutical and Biotechnology Companies
Others
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Agilent Technologies Inc., Applied Spectral Imaging Inc., Biological Industries, Bio-RAD Laboratories Inc., BioView Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Illumina Inc., Oxford Gene Technology, Perkinelmer Inc. and Quest Diagnostics Incorporated.